Investing in Orthopedics and Musculoskeletal Disease: A Pre-Seed Lens

Why does musculoskeletal disease burden keep growing regardless of the economic cycle?

Musculoskeletal conditions are, structurally, a function of age and mechanical use, which is what makes the category unusually predictable for an early-stage investor. Osteoarthritis, the gradual breakdown of joint cartilage most common in the knee, hip, hand, and spine, rises in prevalence with age and with prior joint injury, and public-health data has long shown it to be among the most common causes of chronic pain and disability in older adults. There is no plausible scenario in which its prevalence declines over the next few decades, because the population at risk, people living into their seventies, eighties, and beyond, is itself growing as a share of the population across nearly every developed market.

Spine conditions sit alongside osteoarthritis as a second major pillar of disease burden. Degenerative disc disease, spinal stenosis, and spondylolisthesis accumulate with age and with cumulative mechanical loading, and low back pain in particular has long been identified in public-health research as among the leading causes of years lived with disability worldwide. Sports and activity related injury, ACL and meniscus tears, rotator cuff injury, tendon and ligament damage, adds a second, less age dependent stream of demand, driven both by competitive and youth athletics and by an aging but increasingly active adult population that continues running, cycling, and playing recreational sports well past midlife.

Osteoporosis closes the loop. It is a systemic loss of bone density and microarchitectural strength that increases the risk of fragility fractures at the hip, spine, and wrist, and it disproportionately affects postmenopausal women because of the drop in estrogen that follows menopause, since estrogen helps regulate bone turnover. Hip fracture in an elderly patient is not a minor event, it is widely associated in clinical literature with a meaningful decline in subsequent independence and health status, which is part of why prevention and fixation of osteoporotic fractures is its own significant slice of the orthopedic device market.

Taken together, these four conditions describe a disease burden that grows on a demographic clock rather than a scientific one. An investor does not need a breakthrough discovery to expect that demand for joint, spine, and fracture care will be materially higher in twenty years than it is today, given known population aging trends. That is a rare property in healthcare investing, and it is the starting point for why we take the category seriously at the earliest stage.

Why is orthopedics a device-dominated field rather than a drug-dominated one?

Most of healthcare investing is organized around molecules, small molecule drugs, biologics, gene and cell therapies, that intervene in a biological pathway. Orthopedics is different. Once cartilage has worn away, a disc has degenerated, or a bone has fractured, the underlying problem is structural, and structural problems are, in large part, addressed mechanically. That is why the commercial center of gravity in musculoskeletal disease has long been implants, instruments, and hardware rather than pharmacology, and why the category rewards a different kind of founding team than a therapeutics company does.

Joint replacement implants, principally total hip and total knee arthroplasty, replace the damaged articulating surfaces of a joint with a combination of metal, ceramic, and polyethylene components, and represent one of the largest and most mature segments of the orthopedic device market. Shoulder, ankle, and partial joint replacement are smaller but growing adjacent categories, and implant design continues to iterate on materials, fixation method, whether the components are cemented or press fit for bone ingrowth, and the geometry of the articulating surface, all in pursuit of longer implant survivorship and better restoration of natural motion.

Spine hardware is a second major pillar: pedicle screws, rods, and interbody cages used to achieve spinal fusion in patients with degenerative disc disease, spondylolisthesis, or deformity, alongside a smaller motion preserving category of artificial discs positioned as an alternative to fusion. Robotic assisted and navigation guided surgery has become an increasingly common layer on top of both joint and spine procedures, using preoperative imaging and intraoperative tracking to guide bone resection and implant placement with greater consistency than manual technique alone, though the evidence on whether this translates into meaningfully better long-term patient outcomes, as opposed to more consistent alignment, is still accumulating.

Orthobiologics round out the category: bone graft substitutes, demineralized bone matrix, platelet-rich plasma, and cell-based products used to support healing in fracture repair, spinal fusion, and soft tissue injury. This is a genuinely hybrid space, some products are regulated as devices, others fall under separate biologics or human cell and tissue frameworks depending on how extensively the tissue is processed or manipulated, and a founding team needs to know from day one which bucket its product falls into, because that decision drives the entire regulatory and reimbursement plan.

What regulatory path do orthopedic devices actually follow?

The FDA classifies medical devices into three risk based tiers, and where an orthopedic product lands in that classification is one of the first and most consequential diligence questions we ask. Class I devices, the lowest risk, are subject mainly to general controls, and most are exempt from premarket review. Class II devices, moderate risk, are the largest category, and most require 510(k) premarket notification, in which a company demonstrates that its device is substantially equivalent in intended use and technological characteristics to a legally marketed predicate device already on the market. Class III devices, generally the highest risk or the most novel, typically require premarket approval, or PMA, which demands actual clinical evidence of safety and effectiveness rather than a comparison to something already cleared.

The great majority of orthopedic hardware, hip stems, knee components, spinal pedicle screw systems, standard instrumentation, clears through the 510(k) pathway, because these are incremental refinements of well established device categories with decades of predicates behind them. That changes when a company introduces a genuinely novel material composition, an unprecedented mechanism of action, or a combination product that pairs a device with a biologic or drug component. Motion preserving spinal disc replacements, for example, have historically needed to go through PMA because they represented a new device category rather than an incremental variation on fusion hardware. Where no valid predicate exists but the underlying risk is still low to moderate, the De Novo classification pathway offers a middle route, one that creates a brand-new device category and, notably, can itself become a predicate that later entrants cite in their own 510(k) filings.

For a pre-seed investor, this distinction matters a great deal, because the practical capital and timeline required to reach a marketed orthopedic device can look very different from a therapeutics program. A well-reasoned 510(k) strategy, with a real predicate identified, is generally faster and less capital intensive than the investigational new drug through new drug application pathway that a therapeutics company must walk. That does not make it easy: rigorous bench testing, biocompatibility studies, and often cadaver or large-animal data are still required, and a founding team that treats 510(k) as a shortcut rather than a real regulatory discipline is a warning sign, not a reason for comfort.

Why is the site of care shifting from the hospital to the outpatient center, and why does it matter for founders?

For decades, hip and knee replacement and many spinal fusions were performed almost exclusively as inpatient procedures, with multi-day hospital stays built around post-operative monitoring, pain management, and early mobility support. That has been changing steadily. Improvements in regional anesthesia, multimodal pain control that reduces reliance on opioids, blood loss reducing surgical technique, and less invasive approaches to exposure have together made it possible to send a growing share of patients home the same day, or within about twenty-four hours, rather than keeping them in a hospital bed for several nights.

Medicare and commercial payers have, over time, expanded which orthopedic procedures are reimbursable outside the inpatient-only setting, and that policy direction, combined with the underlying clinical advances, has contributed to a meaningful shift of procedure volume into hospital outpatient departments and freestanding ambulatory surgery centers, or ASCs. This is not a minor administrative detail. It changes who the customer is, how a product needs to be priced, and how a device must be engineered.

An ASC typically has a smaller sterile processing footprint, tighter room turnover expectations, and less capital available for large fixed equipment than a hospital system does. A robotic platform or an instrument tray designed only around hospital-scale purchasing and staffing may struggle to gain traction as more elective orthopedic volume moves to these lower-cost settings. Just as important, physician-owners are frequently the decision makers in an ASC, which changes the sales motion for an early-stage device company: adoption depends on convincing a practicing surgeon-investor of both clinical and economic value, not only on navigating a hospital value analysis committee.

Founders building for this decade need to design and price with the ASC in mind from the outset, rather than treat it as a later go-to-market adjustment. We view a device that is ASC-compatible by design, smaller footprint, shorter procedure time, lower total cost of ownership, as generally better positioned than one that only works within a traditional hospital operating room.

What does a fundable pre-seed orthopedic spinout actually look like?

We look for university and teaching-hospital spinouts where the underlying insight came from direct clinical or engineering observation of an unsolved problem in the operating room or clinic, not a technology in search of an application. The strongest teams pair a practicing orthopedic surgeon or biomechanical engineer, someone who has lived the clinical problem, with an operator who has previously taken a device through FDA clearance, a quality system build, or a commercial launch. Two academic co-founders without device operating experience is a common and correctable gap, not a disqualifier, but it is something we probe directly.

A fundable company at this stage typically has an exclusively licensed or assigned patent family from the university’s technology transfer office, with at least a preliminary view on freedom to operate. It has a specific, credible regulatory strategy already articulated, which predicate device or devices it intends to cite for a 510(k), or an honest acknowledgment that its innovation requires a De Novo request or a PMA and what that implies for time and capital. Vague statements about being ’510(k)-able’ without a named predicate are a warning sign.

Early validation matters more than a polished deck. Benchtop mechanical testing, cadaver lab studies, and, where biologically relevant, large-animal data supporting the core claim, whether that is implant fixation strength, fusion rate, or wear characteristics, give us something concrete to underwrite. We also want to see a realistic, milestone-based budget to reach first-in-human use or a limited launch, ideally supplemented in part with non-dilutive funding such as federal SBIR or STTR grants or foundation support, rather than a plan that assumes equity alone will carry the company from bench to bedside.

Finally, we look for teams that already understand, even if they have not yet built, the quality system obligations that will govern them well before commercial launch, design controls and documentation aligned to recognized quality standards such as ISO 13485, and that have given early thought to reimbursement: whether an existing CPT code covers the procedure the device enables, or whether the company will need to pursue a new code and coverage determination, a process that can take considerably longer than FDA clearance itself.

How does Sonnerie evaluate device-heavy deals differently from therapeutics?

As a pre-seed and seed investor writing what is often the first institutional check, we underwrite orthopedic device companies against a genuinely different risk profile than we use for therapeutics. In a drug program, the dominant uncertainty is biological and clinical, whether the molecule works safely and effectively in humans, and that risk is typically resolved through a small number of trial readouts spread over many years. In an orthopedic device program, biological risk is usually more contained, the mechanics of bone, cartilage, and joint motion are comparatively well characterized, and the dominant uncertainties are engineering, manufacturing, adoption, and channel risk instead.

Concretely, our diligence on a device deal asks whether the predicate or regulatory pathway is genuinely as clean as the founders claim, whether the team can actually run a compliant quality system as it scales, whether there is a surgeon champion beyond the founders themselves willing to adopt the device, and whether the product’s design fits or fights the shift toward ambulatory and outpatient care. We also examine unit economics, the realistic cost of goods and gross margin at commercial scale, and the exit landscape, since orthopedics has long had an active roster of strategic acquirers with dedicated corporate development functions scanning for early-stage innovation of exactly this kind.

This different risk profile is part of why the category fits a pre-seed capital-efficiency mandate well. Devices generally reach a validating clinical or commercial milestone faster and with less capital than a therapeutics asset does, which matters to a first check that needs a credible path to a value-inflecting event within a defined runway. The tradeoff is real: adoption in orthopedics can be slow, because surgeon technique and preference change gradually, and any new entrant is competing for operating room time and hospital purchasing attention against large, entrenched incumbents with established sales forces. We underwrite that adoption curve explicitly rather than assuming clinical superiority alone will win the room.

Our operator-led philosophy shows up most clearly here. We favor founding teams that include someone who has actually shipped a device through FDA clearance and through a hospital value analysis committee before, because the difference between a good idea and a fundable company in this category is usually execution discipline, not technical novelty. University spinouts give us access to that first idea, an operator on the team gives us confidence it can become a company. Nothing here is investment advice, and it does not reflect the terms, performance, or existence of any particular Sonnerie fund.